SLXN

+ Watchlist + Portfolio

Silexion Therapeutics Corp

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.41
52-Week Range: $0.37 – $80.00
Market Cap: $2.22M
P/E (TTM): —
EPS (TTM): -19.89
Dividend Yield: —

Advanced Metrics

Price/Book: 0.47
PEG Ratio: —
Return on Equity: -897.46%
Return on Assets: -123.27%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 1.00
Debt/Equity: 6.84
Total Debt: $1.99M
Free Cash Flow: $-7.49M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $-247.94K

SLXN Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$3.23M	$3.71M	$5.82M	$7.14M
Selling, General & Admin	$577.00K	$928.00K	$6.73M	$4.48M
Operating Expenses	$3.86M	$4.68M	$12.57M	$11.63M
Operating Income	-$3.86M	-$4.68M	-$12.57M	-$11.63M
EBITDA	-$3.80M	-$5.03M	-$16.48M	-$11.88M
Pretax Income	-$3.46M	-$5.08M	-$16.51M	-$11.91M
Income Tax	$24.00K	$32.00K	$10.00K	$3.00K
Net Income	-$3.21M	-$4.94M	-$16.44M	-$11.91M
Diluted EPS	-532.46	-818.48	-3949.40	-89.60
Diluted Shares	6038	6038	4163	132951

SLXN Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$8.26M	$4.59M	$1.19M	$5.99M
Current Assets	$8.84M	$4.98M	$2.25M	$6.64M
Total Assets	$9.33M	$5.26M	$2.86M	$7.21M
Current Liabilities	$1.61M	$2.20M	$3.52M	$2.76M
Long-Term Debt	—	—	$2.96M	$1.57M
Total Debt	$271.00K	$171.00K	$4.49M	$2.04M
Total Liabilities	$16.41M	$17.31M	$6.85M	$4.61M
Retained Earnings	-$21.87M	-$26.81M	-$43.25M	-$55.17M
Shareholders' Equity	-$10.66M	-$15.48M	-$3.99M	$2.60M
Working Capital	$7.23M	$2.78M	-$1.27M	$3.88M
Net Debt	—	—	$2.78M	—

SLXN Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$3.33M	-$4.53M	-$8.40M	-$10.82M
Capital Expenditure	-$40.00K	-$12.00K	-$22.00K	-$9.00K
Free Cash Flow	-$3.38M	-$4.54M	-$8.42M	-$10.83M
Depreciation & Amortisation	$57.00K	$45.00K	$25.00K	$14.00K
Stock-Based Compensation	$125.00K	$130.00K	$5.86M	$134.00K
Investing Cash Flow	-$524.00K	$573.00K	-$22.00K	-$14.00K
Financing Cash Flow	$2.75M	$522.00K	$5.10M	$15.64M
Net Change in Cash	-$1.11M	-$3.43M	-$3.31M	$4.81M

SLXN Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$590.00K	$1.02M	$2.16M	$3.38M	$1.37M
Selling, General & Admin	$1.06M	$1.26M	$1.13M	$1.03M	$1.38M
Operating Expenses	$1.65M	$2.28M	$3.29M	$4.41M	$2.75M
Operating Income	-$1.65M	-$2.28M	-$3.29M	-$4.41M	-$2.75M
EBITDA	-$1.72M	-$2.50M	-$3.25M	-$4.40M	-$2.75M
Pretax Income	-$1.74M	-$2.50M	-$3.26M	-$4.41M	-$2.73M
Income Tax	—	$3.00K	$0.00	$0.00	—
Net Income	-$1.74M	-$2.50M	-$3.26M	-$4.41M	-$2.73M
Diluted EPS	-39.00	43.20	-28.80	—	-8.50
Diluted Shares	45194	57952	113265	—	323037

SLXN Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$6.15M	$3.47M	$9.24M	$5.99M	$2.41M
Current Assets	$7.72M	$5.24M	$11.05M	$6.64M	$4.07M
Total Assets	$8.31M	$5.80M	$11.61M	$7.21M	$4.60M
Current Liabilities	$2.40M	$2.15M	$2.79M	$2.76M	$4.06M
Long-Term Debt	$2.99M	$3.19M	$1.54M	$1.57M	—
Total Debt	$3.48M	$3.70M	$2.02M	$2.04M	$1.99M
Total Liabilities	$5.72M	$5.68M	$4.64M	$4.61M	$4.31M
Retained Earnings	-$44.99M	-$47.49M	-$50.75M	-$55.17M	-$57.90M
Shareholders' Equity	$2.59M	$120.00K	$6.98M	$2.60M	$291.00K
Working Capital	$5.33M	$3.09M	$8.27M	$3.88M	$5.00K

SLXN Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$2.45M	-$2.51M	-$2.84M	-$3.02M	-$3.65M
Capital Expenditure	-$6.00K	-$1.00K	—	-$2.00K	—
Free Cash Flow	-$2.46M	-$2.51M	-$2.84M	-$3.02M	-$3.65M
Depreciation & Amortisation	$4.00K	$3.00K	$4.00K	$3.00K	$2.00K
Stock-Based Compensation	$21.00K	$37.00K	$38.00K	$38.00K	$345.00K
Investing Cash Flow	-$6.00K	-$1.00K	$0.00	-$7.00K	$0.00
Financing Cash Flow	$7.43M	-$195.00K	$8.62M	-$221.00K	$83.00K
Net Change in Cash	$4.97M	-$2.70M	$5.78M	-$3.24M	-$3.56M

Market Snapshot

About

Silexion Therapeutics Corp is a biopharmaceutical company focused on developing RNA interference therapeutics for fibrotic diseases. The company is advancing treatments targeting tissue scarring conditions affecting various organs. Silexion utilizes proprietary technology to silence genes responsible for excessive collagen production and fibrosis.